FDA approval of Merck’s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi’s Beyfortus. The new Merck product is expected to be discussed by the CDC’s Advisory Committee on Immunization Practices; ACIP will have an entirely new roster at its next meeting after all 17 sitting members were dismissed by Health and Human Services Secretary Robert F. Kennedy Jr.
The post Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use is Gutted appeared first on MedCity News.
